drugset / Trial / NCT03217422
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
RandomizedParallel-groupQuadruple-blindTreatment
Summary
VAY736 dose testing; VAY736 efficacy and safety testing.
Timeline
- Start
- 2018-02-15
- Primary completion
- 2023-12-28
- Completion
- 2025-12-17
Publications
- Cholankeril G, Vierling JM. The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough! Hepatology. 2024 Mar 1;79(3):529-531. doi: 10.1097/HEP.0000000000000597. Epub 2023 Sep 18. No abstract available.
- Chung YY, Rahim MN, Heneghan MA. Autoimmune hepatitis and pregnancy: considerations for the clinician. Expert Rev Clin Immunol. 2022 Apr;18(4):325-333. doi: 10.1080/1744666X.2022.2044307. Epub 2022 Mar 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | — | — |